The market for GLP-1-specific nutrition products is completely unserved, representing a $400M+ immediate opportunity within a broader $3B+ addressable market
Semaglutide is approved or under review for heart failure with preserved ejection fraction, sleep apnoea, metabolic dysfunction-associated steatohepatitis and chronic kidney disease, with each indication increasing the reimbursable patient population
However, dehydration from gastrointestinal side effects or dietary modifications may indirectly affect urine smell
Since rapid weight loss can result in malnutrition, there is a new recommendation that those taking weight management treatments also be screened for malnutrition
This interpretation is further supported when inflammatory responses, cellular survival pathways, and neuroanatomical integrity are considered collectively